Trial · NCT03190213
Adverse events37
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 37
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | Gastrointestinal disorders | Pembrolizumab: All Patients | 3 | 6 | |
| other | Allergic reaction | Immune system disorders | Pembrolizumab: All Patients | 1 | 6 | |
| other | Anal pain | Gastrointestinal disorders | Pembrolizumab: All Patients | 1 | 6 | 2 |
| other | Anorexia | Metabolism and nutrition disorders | Pembrolizumab: All Patients | 2 | 6 | 3 |
| other | Autoimmune disorder | Immune system disorders | Pembrolizumab: All Patients | 1 | 6 | |
| other | Constipation | Gastrointestinal disorders | Pembrolizumab: All Patients | 2 | 6 | |
| other | Dehydration | Metabolism and nutrition disorders | Pembrolizumab: All Patients | 1 | 6 | |
| other | Diarrhea | Gastrointestinal disorders | Pembrolizumab: All Patients | 3 | 6 | 5 |
| other | Dyspepsia | Gastrointestinal disorders | Pembrolizumab: All Patients | 1 | 6 | |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Pembrolizumab: All Patients | 1 | 6 | 2 |
| other | Edema limbs | General disorders | Pembrolizumab: All Patients | 2 | 6 | |
| other | Fatigue | General disorders | Pembrolizumab: All Patients | 3 | 6 | 4 |
| other | Headache | Nervous system disorders | Pembrolizumab: All Patients | 1 | 6 | |
| other | Hot flashes | Vascular disorders | Pembrolizumab: All Patients | 1 | 6 | |
| other | Hyperglycemia | Metabolism and nutrition disorders | Pembrolizumab: All Patients | 1 | 6 | 2 |
| other | Hypoxia | Respiratory, thoracic and mediastinal disorders | Pembrolizumab: All Patients | 1 | 6 | |
| other | Infections and infestations - Other: Thrush | Infections and infestations | Pembrolizumab: All Patients | 1 | 6 | |
| other | Infusion related reaction | General disorders | Pembrolizumab: All Patients | 1 | 6 | |
| other | Insomnia | Psychiatric disorders | Pembrolizumab: All Patients | 1 | 6 | 2 |
| other | Lymph node pain | Blood and lymphatic system disorders | Pembrolizumab: All Patients | 1 | 6 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03190213/events